The biotech sector has not seen an IPO in six months. The market has remained frozen amid broader macro pressures and the ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Thousands of employees across the Department of Health and Human Services are set to lose their collective bargaining rights ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

Vanda claims that two generics to its sleep disorder drug Hetlioz were approved despite inadequate data and is requesting ...

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Drugs are being invented and manufactured right here in the U.S. by Americans, for Americans. So why doesn’t the industry ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...